基于抗中性粒细胞胞质抗体的列线图模型对川崎病患儿并发冠状动脉病变风险的预测作用

陈蓉, 张锰, 朱荻绮, 郭颖, 沈捷

Nomogram for predicting the risk of coronary artery lesions in patients with Kawasaki disease based on anti-neutrophil cytoplasmic antibodies

CHEN Rong, ZHANG Meng, ZHU Diqi, GUO Ying, SHEN Jie

表1 训练集和验证集基线资料比较

Tab1 Comparison of baseline characteristics between the training set and validation set

Variable	Training set (n=237)			Validation set (n=103)				P value^①
Variable	CAL (n=58)	NCAL (n=179)	P value		CAL (n=19)	NCAL (n=84)	P value	P value^①
Gender/n(%)			<0.001				0.682	0.897
Male	45 (77.59)	85 (47.49)		12 (63.16)		46 (54.76)
Female	13 (22.41)	94 (52.51)		7 (36.84)		38 (45.24)
Age/month	30.00 (12.25,47.50)	33.00 (18.00,56.50)	0.148	29.00 (15.00,49.50)		31.00 (18.75,52.50)	0.702	0.781
Fever duration before IVIG/n(%)			0.228				0.316	0.941
<5 d	13 (22.41)	26 (14.53)		5 (26.32)		13 (15.48)
≥5 d	45 (77.59)	153 (85.47)		14 (73.68)		71 (84.52)
CRP/(mg·L^-1)	64.80 (37.95,103.03)	63.40 (34.90,95.10)	0.601	81.70 (51.60,109.70)		61.60 (39.78,101.92)	0.161	0.420
NEUT%/%	66.26 (55.21,76.89)	65.70 (53.70,76.78)	0.895	68.21 (55.82,80.45)		67.32 (52.11,74.67)	0.280	0.933
HGB/(g·L^-1)	107.00 (101.00,115.00)	110.00 (103.00,117.00)	0.209	107.00 (101.00,112.50)		110.50 (102.75,116.00)	0.139	0.462
PLT/(×10⁹·L^-1)	332.00 (227.50,452.50)	336.00 (259.00,416.00)	0.702	253.00 (219.50,338.00)		329.50 (262.75,417.00)	0.038	0.170
Na⁺/(mmol·L^-1)	135.60 (134.00,137.25)	137.00 (135.00,138.65)	0.010	136.00 (133.80,137.55)		136.55 (135.00,138.15)	0.190	0.922
ESR/(mm·h^-1)	65.50 (44.75,75.00)	65.00 (48.00,81.00)	0.531	66.00 (54.50,74.00)		71.00 (54.50,87.00)	0.655	0.120
Ferr/(ng·mL^-1)	171.25 (110.67,270.36)	175.52 (130.20,241.20)	0.712	252.60 (152.65,291.90)		167.55 (136.88,272.72)	0.241	0.177
ALT/(IU·L^-1)	27.50 (18.00,48.75)	24.00 (15.50,59.50)	0.356	30.00 (20.00,134.50)		28.00 (18.75,60.00)	0.540	0.215
AST/(IU·L^-1)	33.00 (27.00,47.75)	33.00 (28.00,46.50)	0.731	33.00 (28.00,70.00)		34.00 (26.00,42.50)	0.507	0.579
ALB/(g·L^-1)	34.62±4.36	3 6.66±3.98	0.002	35.22±2.87		36.04±4.59	0.326	0.586
TBIL/(μmol·L^-1)	8.80 (6.12,12.15)	8.20 (5.60,11.45)	0.352	9.10 (4.85,24.05)		8.75 (6.65,11.72)	0.953	0.264
NT-proBNP/(pg·mL^-1)	652.00 (185.50,2460.25)	302.00 (104.00,984.00)	0.014	291.00 (94.50,1528.50)		406.00 (186.50,1189.75)	0.792	0.691
IL-6/(pg·mL^-1)	74.51 (25.09,246.56)	71.00 (33.11,169.65)	0.402	74.39 (35.95,150.71)		80.64 (24.84,167.78)	0.875	0.905
Count of CD3⁺CD4⁺/n	1 173.84 (694.43,1 779.17)	1 183.81 (635.24,2 016.62)	0.857	862.66 (396.05,1 269.99)		1 110.01 (670.87,2 006.53)	0.208	0.724
ANA/n(%)			0.934				0.547	1.000
Positive	12 (20.69)	40 (22.35)		5 (26.32)		17 (20.24)
Negative	46 (79.31)	139 (77.65)		14 (73.68)		67 (79.76)
ANCA/n(%)			0.007				0.002	0.946
Positive	8 (13.79)	6 (3.35)		5 (36.32)		2 (2.38)
Negative	50 (86.21)	173 (96.65)		14 (73.68)		82 (97.62)
IVIG resistance/n(%)			0.008				0.031	0.846
Yes	14 (24.14)	17 (9.50)		6 (31.58)		9 (10.71)
No	44 (75.86)	162 (90.50)		13 (68.42)		75 (89.29)